(Q35172784)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

review article

1 reference

title

What can oncologists learn from HIV? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

author name string

Justin Stebbing

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

publication date

1 July 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

5 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

volume

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

page(s)

438-445

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency

5 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Immunologic abnormalities in homosexual men. Relationship to Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Isolation of a T-Lymphotropic Retrovirus from a Patient at Risk for Acquired Immune Deficiency Syndrome (AIDS)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

An African HIV-1 sequence from 1959 and implications for the origin of the epidemic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Could widespread use of combination antiretroviral therapy eradicate HIV epidemics?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Health care advocacy for AIDS patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Burnout, social support and AIDS volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

International behavioral responses to a health hazard: AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Effect of Nancy Reagan's mastectomy on choice of surgery for breast cancer by US women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Charges of human immunodeficiency virus discrimination in the workplace: the Americans with Disabilities Act in action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

GLQ223: an inhibitor of human immunodeficiency virus replication in acutely and chronically infected cells of lymphocyte and mononuclear phagocyte lineage

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

In pursuit of quality: the National Institute for Clinical Excellence

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Developmental therapeutics and the acquired immunodeficiency syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

1 reference

7 January 2021

A structural model for the retroviral proteases.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Crystal structure of a retroviral protease proves relationship to aspartic protease family

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Structure of HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site locations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Increasing choices for HIV therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

New class of HIV drugs shows promise

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Antiretroviral treatment in resource-poor settings: clinical research priorities

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

1 reference

7 January 2021

Efficacy, safety, and cost of new anticancer drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Surrogacy in HIV-1 clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Complete mutagenesis of the HIV-1 protease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

HIV resistance testing in clinical practice: a Qaly-fied success

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Use of genotypic resistance testing to guide hiv therapy: clinical impact and cost-effectiveness

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Limited patient adherence to highly active antiretroviral therapy for HIV-1 infection in an observational cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Adherence to therapy with oral antineoplastic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Using pharmacokinetic-pharmacodynamic relationships to predict the effect of poor compliance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Therapeutic drug monitoring of HIV-protease inhibitors to assess noncompliance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

High-dose methotrexate: a critical reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Low-dose ritonavir for protease inhibitor pharmacokinetic enhancement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Dose intensity for bolus versus infusion chemotherapy administration: review of the literature for 27 anti-neoplastic agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Quantifying psychiatric comorbidity--lessions from chronic disease epidemiology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Dynamics of HIV epidemics in sub-Saharan Africa: introduction

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Changes in HIV risk behavior following alternative residential programs of drug abuse treatment and AIDS education

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

HIV dynamics and behaviour change as determinants of the impact of sexually transmitted disease treatment on HIV transmission in the context of the Rakai trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Outcomes of a randomized community-level HIV prevention intervention for women living in 18 low-income housing developments

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

The ethics of clinical research in the Third World

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Ethical complexities of conducting research in developing countries

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

Evaluation of quality of life in patients receiving treatment for advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901142-2

7 January 2021

10.1016/S1470-2045(03)01142-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12850195%20AND%20SRC:MED&resulttype=core&format=json

5 November 2019

1 reference